Skip to main content

Table 3 Reduction (improvement) from Baseline in WOMAC Pain. N (%)

From: Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis

   0.03 mg
(N = 7)
0.1 mg
(N = 6)
0.3 mg
(N = 6)
1 mg
(N = 6)
All
(N = 25)
Placebo
(N = 8)
Mean Baseline Score (0-20) 7.57 10.5 8.2 8.33 8.6 8.6
Week 4 20% Reduction 3 (42.9%) 3 (50.0%) 2 (33.3%) 5 (83.3%) 13 (52%) 1 (12.5%)
Week 8 20% Reduction 3 (42.9%) 5 (83.3%) 3 (50.0%) 5 (83.3%) 16 (64%) 3 (37.5%)
Week 12 20% Reduction 4 (57.1%) 5 (83.3%) 3(50.0%) 1 (16.7%) 13 (52%) 4 (50.0%)
Week 24 20% Reduction 4 (57.1%) 5 (83.3%) 5 (83.3%) 1 (16.7%) 15 (60%) 4 (50.0%)
Week 4 50% Reduction 3 (42.9%) 2 (33.3%) 2 (33.3%) 3 (50.0%) 10 (40%) 0 (0.0%)
Week 8 50% Reduction 1 (14.3%) 3 (50.0%) 3 (50.0%) 4 (66.7%) 11 (44%) 0 (0.0%)
Week 12 50% Reduction 0 (0.0%) 3 (50.0%) 2 (33.3%) 1 (16.7%) 6 (24%) 1(12.5%)
Week 24 50% Reduction 0 (0.0%) 5 (83.3%) 3 (50.0%) 1 (16.7%) 9 (36%) 0 (0.0%)
Week 4 70% Reduction 1 (14.3%) 1 (16.7%) 2 (33.3%) 1 (16.7%) 5 (20%) 0 (0.0%)
Week 8 70% Reduction 1 (14.3%) 1 (16.7%) 2 (33.3%) 1 (16.7%) 5 (20%) 0 (0.0%)
Week 12 70% Reduction 0 (0.0%) 2 (33.3%) 2 (33.3%) 0 (0.0%) 4 (16%) 0 (0.0%)
Week 24 70% Reduction 0 (0.0%) 3 (50.0%) 3 (50.0%) 0 (0.0%) 6 (24%) 0 (0.0%)